Blood samples, clinical data from patients
| Patient . | HIV infection . | Sex . | Age, y . | Y after infection . | Treatment (duration) . | CD4+ T cells/mL . | VL log10 RNA copies/mL . |
|---|---|---|---|---|---|---|---|
| 1 | Yes | M | 42 | 2 | teno, emtri, efa (2 y) | ND* | 1.00 |
| 2 | Yes | M | 37 | 2 | tdf, emtri, ataza/rito (2 y) | 517 | 1.00 |
| 3 | Yes | M | 20 | 2 | tdf, emtri, ralteg (6 mo) | 523 | 1.00 |
| 4 | Yes | M | 47 | 2 | teno, emtri, efa (1 y) | 526 | 1.00 |
| 5 | Yes | M | 50 | 2 | teno, efa (2 y) | 548 | 1.00 |
| 7 | Yes | M | 50 | 1.5 | tdf, emtri, efa (17 mo) | 668 | 1.00 |
| 6 | Yes | M | 35 | 1.5 | tdf, emtri, ataza/rito (17 mo) | 693 | 1.00 |
| 8 | Yes | M | 43 | 1.5 | tdf, emtri, darun/rito (15 mo) | 793 | 1.00 |
| Treated, n/median | 0F/8M | 42.5 | 2 | 548 | 1.0 | ||
| 9 | Yes | M | 47 | 10 | / | 494 | 1.63 |
| 10 | Yes | F | 33 | 6 | / | 564 | 2.98 |
| 11 | Yes | F | 29 | 2 | / | 354 | 3.67 |
| 12 | Yes | F | 32 | 4 | / | 279 | 3.79 |
| 13 | Yes | M | 49 | 4 | / | 596 | 4.17 |
| 14 | Yes | F | 38 | 9 | / | 544 | 4.12 |
| 15 | Yes | F | 55 | 5 | / | 328 | 4.25 |
| 16 | Yes | M | 41 | 5 | / | 709 | 4.25 |
| 17 | Yes | M | 39 | 1.5 | / | 300 | 4.27 |
| 18 | Yes | M | 39 | 2 | / | 583 | 4.48 |
| 19 | Yes | M | 47 | 21 | / | 434 | 4.53 |
| 20 | Yes | F | 64 | 9 | / | 477 | 4.56 |
| 21 | Yes | F | 32 | 3 | / | 579 | 4.58 |
| 22 | Yes | M | 33 | 2 | / | 755 | 4.6 |
| 23 | Yes | M | 39 | 2 | / | 569 | 4.98 |
| Untreated, n/median | 7F/8M | 39 | 4.5 | 544 | 4.25 |
| Patient . | HIV infection . | Sex . | Age, y . | Y after infection . | Treatment (duration) . | CD4+ T cells/mL . | VL log10 RNA copies/mL . |
|---|---|---|---|---|---|---|---|
| 1 | Yes | M | 42 | 2 | teno, emtri, efa (2 y) | ND* | 1.00 |
| 2 | Yes | M | 37 | 2 | tdf, emtri, ataza/rito (2 y) | 517 | 1.00 |
| 3 | Yes | M | 20 | 2 | tdf, emtri, ralteg (6 mo) | 523 | 1.00 |
| 4 | Yes | M | 47 | 2 | teno, emtri, efa (1 y) | 526 | 1.00 |
| 5 | Yes | M | 50 | 2 | teno, efa (2 y) | 548 | 1.00 |
| 7 | Yes | M | 50 | 1.5 | tdf, emtri, efa (17 mo) | 668 | 1.00 |
| 6 | Yes | M | 35 | 1.5 | tdf, emtri, ataza/rito (17 mo) | 693 | 1.00 |
| 8 | Yes | M | 43 | 1.5 | tdf, emtri, darun/rito (15 mo) | 793 | 1.00 |
| Treated, n/median | 0F/8M | 42.5 | 2 | 548 | 1.0 | ||
| 9 | Yes | M | 47 | 10 | / | 494 | 1.63 |
| 10 | Yes | F | 33 | 6 | / | 564 | 2.98 |
| 11 | Yes | F | 29 | 2 | / | 354 | 3.67 |
| 12 | Yes | F | 32 | 4 | / | 279 | 3.79 |
| 13 | Yes | M | 49 | 4 | / | 596 | 4.17 |
| 14 | Yes | F | 38 | 9 | / | 544 | 4.12 |
| 15 | Yes | F | 55 | 5 | / | 328 | 4.25 |
| 16 | Yes | M | 41 | 5 | / | 709 | 4.25 |
| 17 | Yes | M | 39 | 1.5 | / | 300 | 4.27 |
| 18 | Yes | M | 39 | 2 | / | 583 | 4.48 |
| 19 | Yes | M | 47 | 21 | / | 434 | 4.53 |
| 20 | Yes | F | 64 | 9 | / | 477 | 4.56 |
| 21 | Yes | F | 32 | 3 | / | 579 | 4.58 |
| 22 | Yes | M | 33 | 2 | / | 755 | 4.6 |
| 23 | Yes | M | 39 | 2 | / | 569 | 4.98 |
| Untreated, n/median | 7F/8M | 39 | 4.5 | 544 | 4.25 |
VL indicates viral load (HIV-1 RNA copies/mL plasma); ND, not done; M, male; F, female; teno, tenofovir; emtri, emtricitabine; efa, efavirenz; ataza, atazanavir; rito, ritonavir; tdf, tenofovir DF; ralteg, raltegravir; darun, darunavir; and /, untreated.
CD4 count was not obtained in the sample studied here but was obtained 3 months before: 325 cells/mL.